Moderna (MRNA) Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
Go back to Moderna (MRNA) Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 108.85 +0.96 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.89 | 52 Week High | $0.52 | |||
| Open | $111.05 | 52 Week Low | $0.08 | |||
| Day High | $111.29 | P/E | N/A | |||
| Day Low | $106.64 | EPS | $-3.80 | |||
| Volume | 3,407,902 | |||||
